Skip to content

Codeine/Paracetamol

    DEA Class;  Rx

    Common Brand Names; Tylenol with Codeine, Tylenol, Tylenol

    • Analgesics, Opioid Combos

    Oral combination of analgesics, which include an opioid agonist
    Used for the treatment of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate
    Acetaminophen doses above the maximum recommended are associated with hepatotoxicity

    For the treatment of mild pain to moderate pain requiring an opioid is appropriate and for which alternative treatments are inadequate.

    Children <12 years

    Post-operative management in children <18 years following tonsillectomy and/or adenoidectomy

    Patients with significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment

    Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within last 14 days

    Known or suspected gastrointestinal obstruction, including paralytic ileus

    Hypersensitivity to codeine, acetaminophen, or ingredients

    Hepatitis or severe hepatic/renal impairment

    Constipation

    Drowsiness

    Hypotension

    Tachycardia or bradycardia

    Confusion

    Dizziness

    False feeling of well being

    Headache

    Lightheadedness

    Malaise

    Paradoxical CNS stimulation

    Restlessness

    Rash

    Urticaria

    Anorexia

    Nausea

    Vomiting

    Xerostomia

    Ureteral spasm

    Decreased urination

    Increased LFTs

    Burning at injection site

    Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplantation and death; risk increases in individuals with underlying liver disease, alcohol ingestion, and/or use of more than 1 acetaminophen-containing product (see Black Box Warnings)

    Acetaminophen: Risk for rare, but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash

    Acetaminophen may cause serious an potentially fatal skin reactions

    Patients with G6PD deficiency

    Use caution in repeated administration in patients with anemia or with cardiovascular, pulmonary, or renal disease

    Use caution in patients with history of porphyria

    May cause hypotension; use with caution in patients with hypovolemia

    Codeine may cause depression; avoid driving car or operating heavy machinery

    Use caution in patients with conditions associated with hypoxia, hypercapnia, upper respiratory obstruction, or debilitated patients

    Pregnancy

    There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if potential benefit justifies potential risk to fetus

    Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in neonate and neonatal opioid withdrawal syndrome shortly after birth

    Inform female patients of reproductive potential that prolonged use of drug during pregnancy can result in neonatal opioid withdrawal syndrome,which may be life-threatening if not recognized and treated

    Lactation:

    Codeine and its active metabolite, morphine, are present in human milk; there are published studies and cases that have reported excessive sedation, respiratory depression, and death in infants exposed to codeine via breast milk; women who are ultra-rapid metabolizers of codeine achieve higher than expected serum levels of morphine, potentially leading to higher levels of morphine in breast milk that can be dangerous in their breastfed infants; in women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent

    There is no information on effects of codeine milk production; because of potential for serious adverse reactions, including excess sedation, respiratory depression, and death in a breastfed infant, breastfeeding is not recommended during treatment

    Withdrawal seizures in newborns whose mothers had taken butalbital-containing drug during pregnancy reported

    NOTE: For combination products containing acetaminophen, total daily intake of acetaminophen from all sources should be considered and may be the dose-limiting consideration for acetaminophen; codeine products.

    Adults

    Acetaminophen 4,000 mg/day PO; codeine 60 mg/dose PO; some clinicians have recommended the following maximum dosages: for pain, codeine 360 mg/day PO; as an antitussive, codeine 120 mg/day PO.

    Geriatric

    Acetaminophen 4,000 mg/day PO; codeine 60 mg/dose PO; some clinicians have recommended the following maximum dosages: for pain, codeine 360 mg/day PO; as an antitussive, codeine 120 mg/day PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    12 years: Safety and efficacy have not been established.
    1 to 11 years: Use is contraindicated.

    Infants

    Use is contraindicated.

    codeine/acetaminophen

    tablet: Schedule III

    • 15mg/300mg
    • 30mg/300mg
    • 60mg/300mg

    oral suspension: Schedule V

    • (12mg/120mg)/5mL